Physician profile
Jeremy Coplan
NPI 1346468600
$298,435.44
in general payments reported to CMS, 2019-2025
14 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Psychosomatic Medicine providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $25K · 2021: $45K · 2022: $41K · 2023: $50K · 2024: $40K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $99K · Consulting Fee: $38K · Travel and Lodging: $8,894 · Food and Beverage: $8,454 · Honoraria: $2,813 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,368.00 |
| Consulting Fee | $37,816.00 |
| Travel and Lodging | $8,893.82 |
| Food and Beverage | $8,453.57 |
| Honoraria | $2,813.00 |
| Education | $160.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $57,901.47 | 2021-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $43,376.86 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43,149.17 | 2022-2025 | Caplyta |
| Abbvie INC. | $41,260.28 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $40,951.22 | 2019-2023 | Austedo |
| Axsome Therapeutics, INC. | $20,867.13 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $16,927.31 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $13,089.97 | 2019-2022 | |
| Allergan, INC. | $11,307.28 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $9,150.52 | 2019-2021 | |
| Corium, LLC | $212.28 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $180.94 | 2019-2021 | |
| Shire North American Group INC | $32.79 | 2019 | |
| Lundbeck LLC | $28.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Coplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.